← All Axogen, INC filings

Axogen, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
AXGN
Axogen, INC
10-K: Axogen Reports Strong Revenue Growth, BLA Approval
Axogen, Inc. reported a 20.2% increase in revenue for 2025, driven by product volume and pricing, alongside FDA approval for its key Avance product.
NASDAQ
AXGN
Axogen, INC
10-K: Axogen Reports Increased Revenue, Awaits FDA Decision on Key Product
Axogen's 2024 10-K filing reveals a revenue increase alongside ongoing efforts to secure FDA approval for its Avance Nerve Graft product.
NASDAQ
AXGN
Axogen, INC
10-K: Axogen Grants Performance-Based Stock Units Under 2019 Incentive Plan
Axogen, Inc. has awarded performance-based restricted stock units to an employee under its 2019 Long-Term Incentive Plan, with vesting contingent on performance goals and continued service.